On the contrary, another study, which characterized the response of ovarian xenograft tumours to the nonhypercalcemic vitamin-D2 derived anticancer agent (MT19c), observed a reduced efficacy of MT19c and cisplatin following stimulation of PPARγ with rosiglitazone, suggesting that PPARγ promotes survival for some ovarian tumour cells [93]. This evidence concerns the gene PPARG and ovarian neoplasm.